Fluvastatin inhibits high glucose-induced nuclear factor kappa B activation in renal tubular epithelial cells

Journal of Nephrology

Volumn 26, Issue 2, 2013, Pages 289-296

  Gao, Ping ^a   Wu, Xiaoyan ^a   Shui, Shui ^a   Jia, Ruhan ^b  

^a WUHAN UNIVERSITY   (China)

^b RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

Fluvastatin; High glucose; Nuclear factor kappa B; p38 mitogenactivated protein kinase

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ALBUMIN; CHOLESTEROL; CREATININE; FLUINDOSTATIN; GLUCOSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MEVALONIC ACID; MITOGEN ACTIVATED PROTEIN KINASE P38; N ACETYL BETA GLUCOSAMINIDASE; TRANSCRIPTION FACTOR RELA; TRIACYLGLYCEROL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DRUG EFFECT; DRUG MECHANISM; ENZYME PHOSPHORYLATION; EPITHELIUM CELL; FEMALE; GEL MOBILITY SHIFT ASSAY; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; KIDNEY TUBULE CELL; NONHUMAN; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEINURIA; RAT; RENAL PROTECTION; TRIACYLGLYCEROL BLOOD LEVEL; UPREGULATION; URINALYSIS; WESTERN BLOTTING;

ACETYLGLUCOSAMINIDASE; ALBUMINURIA; ANIMALS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BLOTTING, WESTERN; CELL LINE; CHOLESTEROL; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; EPITHELIAL CELLS; FATTY ACIDS, MONOUNSATURATED; FEMALE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOHISTOCHEMISTRY; INDOLES; KIDNEY TUBULES; MEVALONIC ACID; NEPHRECTOMY; NF-KAPPA B; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; RATS; RATS, WISTAR; TRIGLYCERIDES;

EID: 84877354352     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.5301/jn.5000128     Document Type: Article

References (21)

1. Tu Y, Jia R, Ding G, Chen L. Effect of atorvastatin on dendritic cells of tubulointerstitium in diabetic rats. BMB Rep. 2010; 43(3):188-192.
2. Rodríguez-Iturbe B, García G. The role of tubulointerstitial inflammation in the progression of chronic renal failure. Nephron Clin Pract. 2010;116(2):c81-c88.
3. Schmid H, Boucherot A, Yasuda Y, et al; European Renal cDNA Bank (ERCB) Consortium. Modular activation of nuclear factor-kappaB transcriptional programs in human diabetic nephropathy. Diabetes. 2006;55(11):2993-3003.
4. Dai T, Natarajan R, Nast CC, et al. Glucose and diabetes: effects on podocyte and glomerular p38MAPK, heat shock protein 25, and actin cytoskeleton. Kidney Int. 2006;69(5):806-814.
5. Devaraj S, Venugopal SK, Singh U, Jialal I. Hyperglycemia induces monocytic release of interleukin-6 via induction of protein kinase c-alpha and -beta. Diabetes. 2005;54(1):85-91.
6. Gao P, Jia RH, Yang DP, et al. Renoprotective effect of combining angiotensin II receptor blockers and statins in diabetic rats. Chin Med J (Engl). 2005;118(7):598-602.
7. Aoyama I, Shimokata K, Niwa T. An oral adsorbent downregulates renal expression of genes that promote interstitial inflammation and fibrosis in diabetic rats. Nephron. 2002; 92(3):635-651.
8. Nauta FL, Boertien WE, Bakker SJ, et al. Glomerular and tubular damage markers are elevated in patients with diabetes. Diabetes Care. 2011;34(4):975-981.
9. Takiyama Y, Harumi T, Watanabe J, et al. Tubular injury in a rat model of type 2 diabetes is prevented by metformin: a possible role of HIF-1α expression and oxygen metabolism. Diabetes. 2011;60(3):981-992.
10. Li L, Emmett N, Mann D, Zhao X. Fenofibrate attenuates tubulointerstitial fibrosis and inflammation through suppression of nuclear factor-κB and transforming growth factor-β1/ Smad3 in diabetic nephropathy. Exp Biol Med (Maywood). 2010;235(3):383-391.
11. Morcos M, Sayed AA, Bierhaus A, et al. Activation of tubular epithelial cells in diabetic nephropathy. Diabetes. 2002; 51(12):3532-3544.
12. Chen HY, Huang XR, Wang W, et al. The protective role of Smad7 in diabetic kidney disease: mechanism and therapeutic potential. Diabetes. 2011;60(2):590-601.
13. Guo RW, Yang LX, Li MQ, Liu B, Wang XM. Angiotensin II induces NF-kappa B activation in HUVEC via the p38MAPK pathway. Peptides. 2006;27(12):3269-3275.
14. Wang J, Huang H, Liu P, et al. Inhibition of phosphorylation of p38 MAPK involved in the protection of nephropathy by emodin in diabetic rats. Eur J Pharmacol. 2006;553(1-3):297-303.
15. Sakai N, Wada T, Furuichi K, et al. Involvement of extracellular signal-regulated kinase and p38 in human diabetic nephropathy. Am J Kidney Dis. 2005;45(1):54-65.
16. Blanco S, Vaquero M, Gómez-Guerrero C, López D, Egido J, Romero R. Potential role of angiotensin-converting enzyme inhibitors and statins on early podocyte damage in a model of type 2 diabetes mellitus, obesity, and mild hypertension. Am J Hypertens. 2005;18(4 Pt 1):557-565.
17. Nezami N, Safa J, Eftekhar-Sadat AT, et al. Lovastatin raises serum osteoprotegerin level in people with type 2 diabetic nephropathy. Clin Biochem. 2010;43(16-17):1294-1299.
18. Nishikawa T, Matsuzawa Y, Suematsu S, Saito J, Omura M, Kino T. Effect of atorvastatin on aldosterone production induced by glucose, LDL or angiotensin II in human renal mesangial cells. Arzneimittelforschung. 2010;60(7):445-451.
19. Weivoda MM, Hohl RJ. The effects of direct inhibition of geranylgeranyl pyrophosphate synthase on osteoblast differentiation. J Cell Biochem. 2011;112(6):1506-1513.
20. Zhang W, Li Q, Wang L, Yang X. Simvastatin ameliorates glomerulosclerosis in Adriamycin-induced-nephropathy rats. Pediatr Nephrol. 2008;23(12):2185-2194.
21. Gu L, Ni Z, Qian J, Tomino Y. Pravastatin inhibits carboxymethyllysine-induced monocyte chemoattractant protein 1 expression in podocytes via prevention of signalling events. Nephron Exp Nephrol. 2007;106(1):e1-e10.